Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
Annovis Bio Inc. (NYSE: ANVS) is leading the development of safe and effective drugs for neurodegenerative diseases, particularly Alzheimer's Disease (AD). The company's primary focus is improving nerve cell health and cognition in neurodegenerative disorders. Buntanetap, Annovis Bio's lead drug candidate, has shown promising results in late-stage clinical trials for both AD and Parkinson's Disease (PD).
Earlier this year, Annovis announced encouraging outcomes from a phase 2/3 clinical trial of buntanetap as an oral therapy for early AD. The study, which involved 353 patients, evaluated buntanetap's efficacy when used alongside standard care medications and assessed its safety profile. These results highlight Annovis Bio's potential to transform Alzheimer's treatment through innovative drug combinations aimed at boosting cognition.
Annovis Bio Inc. (NYSE: ANVS) sta conducendo lo sviluppo di farmaci sicuri ed efficaci per le malattie neurodegenerative, in particolare la malattia di Alzheimer (AD). L'attenzione principale dell'azienda è migliorare la salute delle cellule nervose e la cognizione nei disturbi neurodegenerativi. Buntanetap, il principale candidato farmaco di Annovis Bio, ha mostrato risultati promettenti negli studi clinici di fase avanzata sia per l'AD che per la malattia di Parkinson (PD).
All'inizio di quest'anno, Annovis ha annunciato risultati incoraggianti da uno studio clinico di fase 2/3 su buntanetap come terapia orale per l'AD precoce. Lo studio, che ha coinvolto 353 pazienti, ha valutato l'efficacia di buntanetap quando utilizzato insieme ai farmaci standard e ha analizzato il suo profilo di sicurezza. Questi risultati evidenziano il potenziale di Annovis Bio di trasformare il trattamento dell'Alzheimer attraverso combinazioni innovative di farmaci mirate a potenziare la cognizione.
Annovis Bio Inc. (NYSE: ANVS) está liderando el desarrollo de medicamentos seguros y efectivos para enfermedades neurodegenerativas, especialmente la enfermedad de Alzheimer (AD). El enfoque principal de la empresa es mejorar la salud de las células nerviosas y la cognición en trastornos neurodegenerativos. Buntanetap, el principal candidato a fármaco de Annovis Bio, ha mostrado resultados prometedores en ensayos clínicos de última etapa tanto para la AD como para la enfermedad de Parkinson (PD).
A principios de este año, Annovis anunció resultados alentadores de un ensayo clínico de fase 2/3 de buntanetap como terapia oral para la AD temprana. El estudio, que involucró a 353 pacientes, evaluó la eficacia de buntanetap cuando se usó junto con medicamentos de atención estándar y evaluó su perfil de seguridad. Estos resultados destacan el potencial de Annovis Bio para transformar el tratamiento del Alzheimer a través de combinaciones innovadoras de medicamentos enfocadas en mejorar la cognición.
Annovis Bio Inc. (NYSE: ANVS)는 신경퇴행성 질환, 특히 알츠하이머병(AD)을 위한 안전하고 효과적인 약물 개발을 선도하고 있습니다. 회사의 주요 초점은 신경퇴행성 장애에서 신경 세포의 건강과 인지를 개선하는 것입니다. Buntanetap은 Annovis Bio의 주요 약물 후보로, AD와 파킨슨병(PD) 모두에 대한 후기 임상 시험에서 유망한 결과를 보여주었습니다.
올해 초, Annovis는 초기 AD에 대한 경구 요법으로서의 buntanetap의 2/3상 임상 시험에서 고무적인 결과를 발표했습니다. 이 연구는 353명의 환자가 참여하였으며, 표준 치료 약물과 함께 사용했을 때 buntanetap의 효능과 안전성을 평가했습니다. 이러한 결과는 인지 기능 향상을 목표로 하는 혁신적인 약물 조합을 통해 알츠하이머 치료를 혁신할 수 있는 Annovis Bio의 잠재력을 강조합니다.
Annovis Bio Inc. (NYSE: ANVS) est à la pointe du développement de médicaments sûrs et efficaces pour les maladies neurodégénératives, en particulier la maladie d'Alzheimer (AD). L'objectif principal de l'entreprise est d'améliorer la santé des cellules nerveuses et la cognition dans les troubles neurodégénératifs. Buntanetap, le principal candidat médicament d'Annovis Bio, a montré des résultats prometteurs dans des essais cliniques avancés pour l'AD et la maladie de Parkinson (PD).
Plus tôt cette année, Annovis a annoncé des résultats encourageants d'un essai clinique de phase 2/3 de buntanetap comme thérapie orale pour l'AD précoce. L'étude, qui a impliqué 353 patients, a évalué l'efficacité de buntanetap lorsqu'il était utilisé avec des médicaments de soins standards et a évalué son profil de sécurité. Ces résultats mettent en évidence le potentiel d'Annovis Bio à transformer le traitement de la maladie d'Alzheimer grâce à des combinaisons innovantes de médicaments visant à améliorer la cognition.
Annovis Bio Inc. (NYSE: ANVS) führt die Entwicklung von sicheren und effektiven Medikamenten für neurodegenerative Erkrankungen, insbesondere Alzheimer-Krankheit (AD), an. Der Schwerpunkt des Unternehmens liegt darauf, die Gesundheit der Nervenzellen und die Kognition bei neurodegenerativen Störungen zu verbessern. Buntanetap, der Hauptkandidatenwirkstoff von Annovis Bio, hat in späten klinischen Studien sowohl für AD als auch für Parkinson-Krankheit (PD) vielversprechende Ergebnisse gezeigt.
Zu Beginn dieses Jahres gab Annovis ermutigende Ergebnisse aus einer Phase 2/3-Studie zu buntanetap als oraler Therapie für frühe AD bekannt. Die Studie, an der 353 Patienten beteiligt waren, bewertete die Wirksamkeit von buntanetap in Kombination mit Standardbehandlungen und untersuchte sein Sicherheitsprofil. Diese Ergebnisse unterstreichen das Potenzial von Annovis Bio, die Behandlung von Alzheimer durch innovative Medikamentenkombinationen zu transformieren, die darauf abzielen, die Kognition zu steigern.
- Buntanetap showed efficacy in late-stage clinical trials for both Alzheimer's and Parkinson's Disease
- Phase 2/3 clinical trial for early Alzheimer's Disease yielded promising results
- Large-scale study with 353 patients demonstrates robust clinical trial design
- None.
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Annovis Bio Inc. (NYSE: ANVS) announces the availability of a broadcast titled, “Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition.”
To hear the AudioPressRelease, please visit: The NetworkNewsAudio
To view the full editorial, please visit: https://nnw.fm/ZIUid
Annovis Bio Inc. is at the forefront of the movement to develop new safe and effective drugs for neurodegenerative diseases, including AD. The company has long pursued the goal to improve the health of nerve cells and, in the process, improve cognition in neurodegenerative disorders. The company’s lead drug candidate, buntanetap, has completed late-stage AD and PD clinical trials and was shown to be efficacious in both indications.
Earlier this year, Annovis announced promising results from its phase 2/3 clinical trial of buntanetap as an oral therapy for early AD. The study involved 353 patients and assessed buntanetap’s efficacy on top of standard of care medications as well as its safety.
About Annovis Bio Inc.
Annovis Bio, headquartered in Malvern, Pennsylvania, is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients.
For more information, about the company, please visit www.AnnovisBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS http://nnw.fm/ANVS
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN
FAQ
What is Annovis Bio's (ANVS) lead drug candidate for neurodegenerative diseases?
How many patients were involved in Annovis Bio's (ANVS) phase 2/3 clinical trial for early Alzheimer's Disease?
What was the focus of Annovis Bio's (ANVS) recent clinical trial for Alzheimer's Disease?
What is the primary goal of Annovis Bio (ANVS) in developing drugs for neurodegenerative diseases?
